Palo Alto-based investment firm TCG Crossover Closes TCGX Fund II with $1B in capital. The offering attracted strong support from new and existing limited partners with commitments coming globally from investors in North America, Europe, the Middle East, and Asia.
Read also – Varlo Sports Raises Undisclosed Amount in Seed Funding
“On behalf of the TCGX team, we are proud to have exceeded our target for the Fund II raise and we are pleased with the returns we have delivered for our limited partners during a challenging market,” “Cariad and Giuliano have been instrumental to the foundation of TCGX and their promotions reflect their deep contributions to the firm,”said Dr. Chen Yu, founder, TCG Crossover.
Read also – [Funding alert]HI-Bio Raises $95 Mn Series B Funding to Advance Targeted Therapies
About TCG Crossover
TCGX was founded in 2021 by Dr. Chen Yu is a registered investment advisor based in Palo Alto, California. TCGX invests in both private and public opportunities, focusing on innovative pre-IPO and public drug discovery companies. We invest in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines.
Read also – [Funding alert]Perplexity Raises $73.6M Series B Funding Round
